Risk factors for poor engagement with a smart pillbox adherence intervention among persons on tuberculosis treatment in Ethiopia.
Digital adherence technologies
Drug-sensitive tuberculosis
Ethiopia
Poor engagement
Smart pillbox
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
14 10 2023
14 10 2023
Historique:
received:
17
05
2023
accepted:
05
10
2023
medline:
23
10
2023
pubmed:
15
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Non-adherence to tuberculosis treatment increases the risk of poor treatment outcomes. Digital adherence technologies (DATs), including the smart pillbox (EvriMED), aim to improve treatment adherence and are being widely evaluated. As part of the Adherence Support Coalition to End TB (ASCENT) project we analysed data from a cluster-randomised trial of DATs and differentiated care in Ethiopia to examine individual-factors for poor engagement with the smart pillbox. Data were obtained from a cohort of trial participants with drug-sensitive tuberculosis (DS-TB) whose treatment started between 1 December 2020 and 1 May 2022, and who were using the smart pillbox. Poor engagement with the pillbox was defined as (i) > 20% days with no digital confirmation and (ii) the count of days with no digital confirmation, and calculated over a two evaluation periods (56-days and 168-days). Logistic random effects regression was used to model > 20% days with no digital confirmation and negative binomial random effects regression to model counts of days with no digital confirmation, both accounting for clustering of individuals at the facility-level. Among 1262 participants, 10.8% (133/1262) over 56-days and 15.8% (200/1262) over 168-days had > 20% days with no digital confirmation. The odds of poor engagement was less among participants in the higher stratum of socio-economic position (SEP) over 56-days. Overall, 4,689/67,315 expected doses over 56-days and 18,042/199,133 expected doses over 168-days were not digitally confirmed. Compared to participants in the poorest SEP stratum, participants in the wealthiest stratum had lower rates of days not digitally confirmed over 168-days (adjusted rate ratio [RR Poorest SEP stratum, HIV-positive status, single/living independent and separated/ widowed were associated with poor engagement with smart pillbox among people with DS-TB in Ethiopia. Differentiated care for these sub-groups may reduce risk of non-adherence to TB treatment.
Sections du résumé
BACKGROUND
Non-adherence to tuberculosis treatment increases the risk of poor treatment outcomes. Digital adherence technologies (DATs), including the smart pillbox (EvriMED), aim to improve treatment adherence and are being widely evaluated. As part of the Adherence Support Coalition to End TB (ASCENT) project we analysed data from a cluster-randomised trial of DATs and differentiated care in Ethiopia to examine individual-factors for poor engagement with the smart pillbox.
METHODS
Data were obtained from a cohort of trial participants with drug-sensitive tuberculosis (DS-TB) whose treatment started between 1 December 2020 and 1 May 2022, and who were using the smart pillbox. Poor engagement with the pillbox was defined as (i) > 20% days with no digital confirmation and (ii) the count of days with no digital confirmation, and calculated over a two evaluation periods (56-days and 168-days). Logistic random effects regression was used to model > 20% days with no digital confirmation and negative binomial random effects regression to model counts of days with no digital confirmation, both accounting for clustering of individuals at the facility-level.
RESULTS
Among 1262 participants, 10.8% (133/1262) over 56-days and 15.8% (200/1262) over 168-days had > 20% days with no digital confirmation. The odds of poor engagement was less among participants in the higher stratum of socio-economic position (SEP) over 56-days. Overall, 4,689/67,315 expected doses over 56-days and 18,042/199,133 expected doses over 168-days were not digitally confirmed. Compared to participants in the poorest SEP stratum, participants in the wealthiest stratum had lower rates of days not digitally confirmed over 168-days (adjusted rate ratio [RR
CONCLUSION
Poorest SEP stratum, HIV-positive status, single/living independent and separated/ widowed were associated with poor engagement with smart pillbox among people with DS-TB in Ethiopia. Differentiated care for these sub-groups may reduce risk of non-adherence to TB treatment.
Identifiants
pubmed: 37838677
doi: 10.1186/s12889-023-16905-z
pii: 10.1186/s12889-023-16905-z
pmc: PMC10576388
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2006Subventions
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
BMJ Open. 2023 Mar 14;13(3):e068685
pubmed: 36918242
J Epidemiol Community Health. 2018 May;72(5):369-375
pubmed: 29352014
BMC Public Health. 2011 Sep 09;11:696
pubmed: 21906291
BMJ Open. 2014 Apr 09;4(4):e004362
pubmed: 24719431
Int J Environ Res Public Health. 2020 Aug 04;17(15):
pubmed: 32759876
BMC Infect Dis. 2021 Jul 31;21(1):725
pubmed: 34332550
Soc Sci Med. 2006 Apr;62(7):1768-84
pubmed: 16226363
Arch Public Health. 2022 Mar 14;80(1):78
pubmed: 35287725
Ann Am Thorac Soc. 2020 Apr;17(4):438-449
pubmed: 31860328
Indian J Tuberc. 2018 Jan;65(1):41-47
pubmed: 29332647
Tuberc Res Treat. 2021 Mar 30;2021:6685039
pubmed: 33859843
Glob Health Action. 2018;11(1):1510592
pubmed: 30394200
J Infect Dis. 2015 May 15;211(10):1607-15
pubmed: 25312040
AIDS. 2016 Apr 24;30(7):1099-109
pubmed: 26752280
BMJ Open. 2022 Jan 3;12(1):e056009
pubmed: 34980628
Elife. 2021 May 14;10:
pubmed: 33988506
Int J Epidemiol. 2001 Aug;30(4):668-77
pubmed: 11511581
Milbank Q. 2004;82(1):5-99
pubmed: 15016244
Pan Afr Med J. 2014 Jan 17;17:26
pubmed: 24932337
Int J Equity Health. 2019 Jul 31;18(1):121
pubmed: 31366362
Bull World Health Organ. 2008 Mar;86(3):B-D
pubmed: 18368191
Ann Intern Med. 2008 Nov 18;149(10):689-97
pubmed: 19017587
Tuberc Res Treat. 2020 Jan 07;2020:7401045
pubmed: 31969998
BMC Infect Dis. 2021 Nov 10;21(1):1149
pubmed: 34758737
Acad Emerg Med. 2011 Oct;18(10):1099-104
pubmed: 21996075
BMC Res Notes. 2018 Oct 1;11(1):691
pubmed: 30285907
PLoS One. 2012;7(3):e32140
pubmed: 22427820
PLoS One. 2016 Apr 07;11(4):e0152900
pubmed: 27054714
Med Sci Monit. 2019 Mar 14;25:1928-1935
pubmed: 30869079
BMC Public Health. 2010 Oct 28;10:651
pubmed: 21029405
J Glob Health. 2021 Jan 30;11:04003
pubmed: 33643634
Ann Intern Med. 2000 Jul 4;133(1):21-30
pubmed: 10877736
J Health Popul Nutr. 2021 Nov 27;40(1):49
pubmed: 34838120
Soc Sci Med. 2015 Mar;128:316-26
pubmed: 25577953
Soc Sci Med. 2009 Jun;68(12):2240-6
pubmed: 19394122
PLoS Med. 2015 Sep 15;12(9):e1001876
pubmed: 26372470
PLoS One. 2019 Jan 10;14(1):e0210422
pubmed: 30629684
Sci Rep. 2022 Jan 14;12(1):745
pubmed: 35031658
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
Lancet. 2001 Sep 8;358(9284):833-6
pubmed: 11564510